AndroGel Side Effects: Withdrawal and Discontinuation Syndrome

AndroGel is the brand name for testosterone 1% and 1.62% transdermal gel, a topical androgen approved by the FDA since 2000 for men with confirmed hypogonadism due to primary testicular failure or hypothalamic-pituitary disease. It is not the same product as testosterone injections, pellets, or other transdermal systems, though the withdrawal physiology overlaps across testosterone formulations.

Direct answer: Stopping AndroGel does not cause a classic drug withdrawal in the sedative or opioid sense. Instead, exogenous testosterone has suppressed the hypothalamic-pituitary-gonadal (HPG) axis, so when the gel is stopped, testosterone falls quickly while the body's own hormone-signaling system needs time to restart. The result is a return of hypogonadal symptoms, sometimes worse than before treatment because the drop is abrupt, that typically improves over months but occasionally persists for a year or longer in men with long treatment histories or pre-existing testicular dysfunction. The FDA label for AndroGel states that abrupt discontinuation in hypogonadal men may result in return of hypogonadal symptoms and that suppression of spermatogenesis is an expected pharmacologic effect of testosterone therapy.

The useful clinical question is not simply "will withdrawal happen," but which of two situations a symptomatic man is in after stopping: transient HPG axis lag that will resolve on its own, or unmasked primary or long-standing secondary hypogonadism that will not recover without treatment. That distinction, not the symptom list itself, determines whether watchful waiting, a bridging medication, or specialist referral is the right next step.

Why stopping causes symptoms at all

During testosterone therapy, circulating testosterone signals the hypothalamus and pituitary to reduce GnRH, LH, and FSH output. The testes, receiving less LH stimulation, produce less of their own testosterone and may show reduced volume. When the gel is stopped, exogenous testosterone clears from the body within days, but the suppressed pituitary and testes do not resume normal output immediately. The gap between the drug leaving the system and the body's own axis restarting is what produces symptoms.

This is a real and expected pharmacologic phenomenon, not a fringe concern. It is acknowledged directly in the AndroGel prescribing information.

What differs between men

• Duration of use. Men treated for many years generally take longer to recover axis function than men treated for a few months, though there is no single validated cutoff and individual variation is substantial.
• Baseline testicular reserve. Men with primary hypogonadism (for example, from Klinefelter syndrome, mumps orchitis, or prior chemotherapy) may never fully recover endogenous production regardless of how long the pituitary is given to restart, because the testes themselves are impaired.
• Age. Testosterone production declines gradually with age in most men, so a man who started TRT in his 50s may return, after stopping, to a baseline that was already low rather than to a "normal" young-adult level.
• Underlying primary hypogonadism. In these men, stopping does not reveal a temporary lag, it unmasks a hormone deficiency that was present before treatment and requires ongoing management.

Timeline: what tends to happen and when

Exact percentages and day-by-day figures from small studies vary and should be treated as approximate rather than as guarantees for an individual patient. The general pattern reported in clinical experience and in the product label is:

Days 1 to 14 (acute phase). Serum testosterone falls within roughly 24 to 72 hours of the last gel application. Fatigue, low mood, irritability, reduced libido, and sleep disruption are the earliest and most commonly reported symptoms. Hot flashes occur in a meaningful minority of men during this window.

Weeks 2 to 12 (prolonged phase). This is generally the period of greatest psychological burden. Mood symptoms, including clinically significant depression, have been reported to be most intense several weeks after cessation rather than immediately, and men with a personal or family history of mood disorders appear to be at higher risk of a difficult course. Reduced muscle mass and increased fat accumulation become more noticeable as the hormonal deficit persists.

Months 3 to 18 (recovery or persistence). In men with intact testes and a shorter treatment history, LH and FSH typically begin rising within weeks and total testosterone often returns to a functional range within three to six months. Men with longer treatment courses, older age, obesity, or pre-existing testicular dysfunction may remain symptomatic well beyond six months. Sperm counts recover more slowly than testosterone because spermatogenesis depends on FSH-driven Sertoli cell support in addition to LH-driven testosterone, and recovery is generally measured in months rather than weeks.

What is established versus what is not. It is established that exogenous testosterone suppresses the HPG axis and that stopping produces a measurable, often symptomatic, fall in serum testosterone. It is plausible but not rigorously quantified at the population level exactly what proportion of men experience each individual symptom, or the precise week-by-week probability of recovery. It is not established that any single symptom timeline applies uniformly across ages, doses, or durations of use, and specific percentage figures circulating in patient materials should be treated as approximations pending verification against the primary literature rather than as precise predictions.

Symptoms during withdrawal versus other AndroGel adverse effects

Symptoms tied to falling testosterone after cessation typically include fatigue, decreased libido, erectile difficulty, low mood or depression, irritability, hot flashes, reduced muscle mass and strength, increased body fat, and sleep disturbance. Bone density can decline with prolonged untreated hypogonadism, though clinically meaningful loss generally requires more than a few weeks of deficiency.

On-treatment adverse effects distinct from withdrawal. These are risks that occur while a man is using AndroGel, not after stopping it, and they should not be confused with withdrawal. The FDA label carries a boxed warning about secondary testosterone exposure to women and children through skin contact, and testosterone gel is a Schedule III controlled substance with recognized abuse and dependence potential. Reported on-treatment risks include erythrocytosis (elevated red blood cell count), acne, application-site skin reactions, and cardiovascular safety concerns that the FDA has required be addressed in labeling for all testosterone products.

Rare adverse events reported through postmarket surveillance for testosterone products generally include priapism, worsening of underlying polycythemia vera, sleep apnea aggravation, and allergic reactions to gel components. The FDA's public adverse event database (FAERS) collects these reports, though FAERS data reflects voluntary and passive reporting and cannot establish incidence rates or causation on its own (FAERS Public Dashboard).

Cardiovascular and safety context that affects the decision to stop

In 2015 the FDA required labeling changes across testosterone products stating that benefit and safety had not been established for age-related low testosterone alone, and added a warning about venous thromboembolism risk. A large randomized cardiovascular safety trial in men with hypogonadism and cardiovascular risk factors (commonly referred to as TRAVERSE, published in 2023) evaluated cardiovascular outcomes with testosterone therapy; the exact effect size reported in that trial is not reproduced here because the citation available for this draft could not be confirmed against the correct publication, and any specific hazard ratio should be verified against the primary trial report before being used in patient-facing material. What can be stated without that figure: cardiovascular risk should be assessed before starting testosterone therapy, monitored during use, and considered again during the withdrawal period, because a falling testosterone level can transiently affect insulin sensitivity and lipid measures in men with existing cardiovascular disease.

Managing the withdrawal period

Three approaches are used in practice, with different evidence quality behind each.

Watchful waiting with lifestyle support. For men with a shorter treatment history, no pre-existing testicular disease, and testosterone that has not fallen to a severely low level, resistance training, sleep optimization, and weight management may support axis recovery, and this avoids pharmacologic intervention entirely. This approach is reasonable only when mood symptoms are mild and there is a monitoring plan in place, not as a default for every patient.

Clomiphene citrate. Clomiphene blocks estrogen receptor feedback at the hypothalamus and pituitary, which can raise LH, FSH, and endogenous testosterone. It is used off-label for this purpose and has an advantage over testosterone re-initiation in men who want to preserve sperm production, since it does not directly suppress spermatogenesis. Reported response rates and treatment durations vary across small studies; a clinician should discuss expected time to response (commonly framed in weeks, not days) rather than a fixed percentage.

Human chorionic gonadotropin (hCG). hCG mimics LH and stimulates the testes directly, bypassing the pituitary. It is generally considered when testicular atrophy is present or when faster symptomatic relief is desired, but it does not restore FSH-dependent spermatogenesis on its own, so men pursuing fertility recovery may need additional therapy.

Neither clomiphene nor hCG for this purpose is FDA-approved for post-TRT recovery; both represent off-label use grounded in physiologic reasoning and observational clinical experience rather than large randomized trials specific to this indication. Deciding among these options, or choosing not to intervene at all, is an individualized medical decision that depends on lab values, symptom severity, and fertility goals, and should not be made from a general article alone.

Decision framework: what changes what a reader should do

This framework does not replace an individualized medical evaluation. It organizes the small number of facts that actually change the recommended next step.

Red flags that warrant urgent, not routine, care: thoughts of self-harm, chest pain or new shortness of breath, sudden severe headache or vision change, or a sustained painful erection. These require immediate medical attention rather than watchful waiting regardless of where a reader falls in the table above.

Monitoring after stopping

A reasonable laboratory schedule, consistent with general endocrinology practice for men stopping testosterone therapy, checks total testosterone, LH, and FSH at roughly 4 to 6 weeks after the last dose, again at 10 to 12 weeks, and at 6 and 12 months if recovery is incomplete. A complete blood count can confirm that any treatment-related erythrocytosis is resolving. Symptom tracking with a validated tool such as the Aging Males' Symptoms scale, compared against a pre-cessation baseline if one was recorded, gives an objective reference point rather than relying on memory of how a man felt before starting therapy originally.

Special populations

Men concerned about fertility. Because spermatogenesis suppression is common during testosterone therapy and recovers more slowly than testosterone itself, men considering future paternity should discuss sperm banking before starting any testosterone product, and should have semen analysis rechecked in the months after stopping rather than assuming automatic recovery.

Older men. Men with age-related declines in testicular reserve may not return fully to the testosterone level they had before starting therapy, since aging itself lowers testosterone independent of TRT. Bone density gained during treatment can decline again after stopping, which supports continued monitoring in men over 50 rather than a single post-cessation check.

Men with cardiovascular disease. The transition period after stopping deserves the same cardiovascular attention as the treatment period itself, given the FDA's 2015 labeling action on testosterone products generally.

What is established, what is plausible, and what is not established

Established: AndroGel suppresses the HPG axis during use; stopping causes testosterone to fall within days; the FDA label states this can cause a return of hypogonadal symptoms; testosterone products carry FDA warnings for cardiovascular risk assessment, venous thromboembolism, and secondary exposure through skin contact.

Plausible but not tightly quantified for this specific population: the exact percentage of men experiencing each symptom, the precise week-by-week probability of testosterone or fertility recovery, and the comparative benefit of clomiphene versus hCG versus watchful waiting, since much of this evidence comes from small studies or extrapolation from broader hypogonadism research rather than large trials in men specifically discontinuing AndroGel.

Not established: that a specific tapering schedule reduces withdrawal severity compared with stopping the gel outright. No controlled trial demonstrating this was identified for this article, and the AndroGel label does not mandate a taper.